MannKind gained ‘new credibility’ for Afrezza at ADA, says H.C. Wainwright

Wainwright analyst Oren Livnat said MannKind materially increased Afrezza’s relevance and gained “new credibility” with multiple data presentations, including a well-attended symposium and oral presentation, at the American Diabetes Association meeting that was just held. He called the event an “eye-opening experience” that showed Afrezza’s defining differentiation is not that it is inhalable, but that it “really is the best meal-time insulin, full stop.” Following the ADA event, Livnat reiterated his Buy rating and $5 target on MannKind shares.

https://bit.ly/2tCnf80